| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Oncternal Therapeutics Inc (NASDAQ: ONCT)
ONCT Technical Analysis
5
| As on 9th Jun 2023 ONCT STOCK Price closed @ 0.32 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 1.33 & Strong Sell for SHORT-TERM with Stoploss of 2.02 we also expect STOCK to react on Following IMPORTANT LEVELS. |
ONCTSTOCK Price
| Open | 0.31 | Change | Price | % |
| High | 0.37 | 1 Day | 0.01 | 3.23 |
| Low | 0.31 | 1 Week | 0.04 | 14.29 |
| Close | 0.32 | 1 Month | 0.00 | 0.00 |
| Volume | 489600 | 1 Year | -2.32 | -87.88 |
| 52 Week High 2.64 | 52 Week Low 0.28 | ||||
NASDAQ USA Most Active Stocks
| TSLA | 244.40 | 4.06% |
| TTOO | 0.07 | -12.50% |
| SOFI | 8.18 | 0.74% |
| FFIE | 0.33 | 6.45% |
| PONO | 1.72 | 2.38% |
| AMD | 124.92 | 3.20% |
| IDEX | 0.06 | 0.00% |
| NKLA | 0.70 | 14.75% |
| AMZN | 123.43 | -0.66% |
| AAPL | 180.96 | 0.22% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| ONCT Daily Charts |
ONCT Intraday Charts |
Whats New @ Bazaartrend |
ONCT Free Analysis |
|
|
ONCT Important Levels Intraday
| RESISTANCE | 0.44 |
| RESISTANCE | 0.40 |
| RESISTANCE | 0.38 |
| RESISTANCE | 0.35 |
| SUPPORT | 0.29 |
| SUPPORT | 0.26 |
| SUPPORT | 0.24 |
| SUPPORT | 0.20 |
ONCT Forecast May 2024
| 4th UP Forecast | 1.59 |
| 3rd UP Forecast | 1.18 |
| 2nd UP Forecast | 0.93 |
| 1st UP Forecast | 0.68 |
| 1st DOWN Forecast | -0.04 |
| 2nd DOWN Forecast | -0.29 |
| 3rd DOWN Forecast | -0.54 |
| 4th DOWN Forecast | -0.95 |
ONCT Weekly Forecast
| 4th UP Forecast | 1.13 |
| 3rd UP Forecast | 0.87 |
| 2nd UP Forecast | 0.71 |
| 1st UP Forecast | 0.55 |
| 1st DOWN Forecast | 0.09 |
| 2nd DOWN Forecast | -0.07 |
| 3rd DOWN Forecast | -0.23 |
| 4th DOWN Forecast | -0.49 |
ONCT Forecast2024
| 4th UP Forecast | 5 |
| 3rd UP Forecast | 3.5 |
| 2nd UP Forecast | 2.57 |
| 1st UP Forecast | 1.64 |
| 1st DOWN Forecast | -1 |
| 2nd DOWN Forecast | -1.93 |
| 3rd DOWN Forecast | -2.86 |
| 4th DOWN Forecast | -4.36 |
Oncternal Therapeutics Inc ( NASDAQ USA Symbol : ONCT )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
ONCT Business Profile
Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical need. Its pipeline includes cirmtuzumab, an investigational monoclonal antibody that is being evaluated in a Phase 1/2 clinical trial in combination with ibrutinib for the treatment of patients with B-cell lymphoid malignancies, including mantle cell lymphoma and chronic lymphocytic leukemia. The company also develops a chimeric antigen receptor T cell therapy that targets Receptor tyrosine kinase-like Orphan Receptor 1, which is in preclinical development as a potential treatment for hematologic cancers and solid tumors. In addition, it is developing TK216, an investigational small molecule that inhibits the E26 Transformation Specific family of oncoproteins. Oncternal Therapeutics, Inc. has license agreements with the Regents of the University of California; Georgetown University; Shanghai Pharmaceutical (USA) Inc.; Selexis S.A.; and University of Tennessee Research Foundation. Oncternal Therapeutics, Inc. has a research collaboration with Celularity Inc. to evaluate placental derived-cellular therapies targeting receptor-tyrosine kinase-like Orphan Receptor 1. The company is headquartered in San Diego, California. Address: 12230 El Camino Real, San Diego, CA, United States, 92130
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service